BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

被引：0

作者：

Kim, D.

Saglio, G.

Martinelli, G.

Shou, Y.

Stein, A. M.

Woodman, R. C.

Kantarjian, H.

Hughes, T. P.

Radich, J. P.

Hochhaus, A.

机构：

[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[2] Univ Turin, San Luigi Gonzaga Hosp, Orbassano, Italy

[3] Inst Hematol, Bologna, Italy

[4] Novartis Inst BioMed Res, Cambridge, MA USA

[5] Novartis Pharmaceut, Cambridge, MA USA

[6] Novartis Pharmaceut, E Hanover, NJ USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] SA Pathol, Dept Haematol, Adelaide, SA, Australia

[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[10] Univ Klinikum Jena, Jena, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.6567

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6567

引用

页数：1

共 50 条

[31] EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR [J].

Branford, S. ;

Kamel-Reid, S. ;

Bendit, I. ;

Etienne, G. ;

Guerci-Bresler, A. ;

Hughes, T. P. ;

Lipton, J. H. ;

Leber, B. ;

Spector, N. ;

Steegmann, J. L. ;

Acharya, S. ;

Collins, L. ;

Dalal, D. ;

Cervantes, F. .

HAEMATOLOGICA, 2014, 99 :532-532

[32] The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up [J].

Hughes, Timothy P. ;

Kim, Dong-Wook ;

Etienne, Gabriel ;

De Souza, Carmino ;

Kurokawa, Mineo ;

Kalaycio, Matt ;

Saglio, Giuseppe ;

Larson, Richard A. ;

Kantarjian, Hagop M. ;

Hoenekopp, Albert ;

Shou, Yaping ;

Yu, Richard ;

Blakesley, Rick E. ;

Rosti, Gianantonio ;

Hochhaus, Andreas .

BLOOD, 2011, 118 (21) :1184-1185

[33] DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) [J].

Hochhaus, A. ;

Mueller, M. C. ;

Cortes, J. ;

Kim, D. W. ;

Matloub, Y. ;

Ploughman, L. ;

Hughes, T. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :371-372

[34] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis [J].

Lipton, Jeffrey H. ;

le Coutre, Philipp D. ;

Wang, Jim ;

Yang, Mindy ;

Szczudlo, Tomasz ;

Giles, Francis .

BLOOD, 2008, 112 (11) :1110-1110

[35] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) [J].

Niu, X. ;

Hay, J. .

VALUE IN HEALTH, 2012, 15 (04) :A209-A210

[36] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). [J].

Le Coutre, P. D. ;

Ottmann, O. ;

Gatterman, N. ;

Larson, R. ;

Rafferty, T. ;

Alland, L. ;

Tavorath, R. ;

Giles, F. ;

O'Brien, S. G. ;

Kantarjian, H. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :344S-344S

[37] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP) [J].

Zhou, L. ;

Hu, P. ;

Meng, F. ;

Wang, J. ;

Wang, C. ;

Hu, Z. ;

Shen, Z. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[38] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) [J].

Giles, Francis J. ;

le Coutre, Phillip ;

Bhalla, Kapil N. ;

Ossenkoppele, Gert ;

Alimena, Giuliana ;

Haque, Ariful ;

Gallagher, Neil ;

Kantarjian, Hagop M. .

BLOOD, 2007, 110 (11) :311A-312A

[39] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia [J].

Hoyle, Martin ;

Rogers, Gabriel ;

Moxham, Tiffany ;

Liu, Zulian ;

Stein, Ken .

VALUE IN HEALTH, 2011, 14 (08) :1057-1067

[40] Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up [J].

Lipton, Jeffrey Howard ;

Hughes, Timothy P. ;

Leber, Brian ;

De Souza, Carmino ;

Dorlhiac-Llacer, Pedro E. ;

Steegmann, Juan Luis ;

Guerci-Bresler, Agnes ;

Schwarer, Anthony P. ;

Cervantes, Francisco ;

Reynolds, John ;

Collins, LaTonya R. ;

Szczudlo, Tomasz K. ;

Spector, Nelson .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →